Home » Stocks » AVDL

Avadel Pharmaceuticals PLC (AVDL)

Stock Price: $6.67 USD 0.06 (0.91%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $7.25 +0.58 (8.70%) Jan 15, 7:39 PM
Market Cap 387.80M
Revenue (ttm) 33.33M
Net Income (ttm) 15.57M
Shares Out 58.21M
EPS (ttm) 0.32
PE Ratio 20.59
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $6.67
Previous Close $6.61
Change ($) 0.06
Change (%) 0.91%
Day's Open 6.58
Day's Range 6.39 - 6.70
Day's Volume 270,792
52-Week Range 4.06 - 11.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 1 month ago

Investors who target growth may want to consider the following small-cap stocks, as they represent companies whose trailing 12-month net earnings per share improved significantly on a year-ove...

Other stocks mentioned: ADUS, IRS
GlobeNewsWire - 1 month ago

DUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxyb...

GlobeNewsWire - 1 month ago

DUBLIN, Ireland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxyb...

GlobeNewsWire - 2 months ago

DUBLIN, Ireland, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxyb...

Seeking Alpha - 2 months ago

Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 2 months ago

Avadel Pharmaceuticals plc's (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

DUBLIN, Ireland, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxyb...

GlobeNewsWire - 2 months ago

DUBLIN, Ireland, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxyb...

GlobeNewsWire - 4 months ago

DUBLIN, Ireland, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium ox...

GlobeNewsWire - 4 months ago

DUBLIN, Ireland, Sept. 14, 2020 (GLOBE NEWSWIRE) --  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium ...

GlobeNewsWire - 4 months ago

DUBLIN, Ireland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium ox...

Zacks Investment Research - 4 months ago

Avadel (AVDL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Seeking Alpha - 5 months ago

Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q2 2020 Results - Earnings Call Transcript

Benzinga - 5 months ago

Shares of Avadel Pharmaceuticals (NASDAQ:AVDL) decreased 1.3% in pre-market trading after the company reported Q2 results.

GlobeNewsWire - 5 months ago

DUBLIN, Ireland, July 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, A...

GlobeNewsWire - 6 months ago

DUBLIN, Ireland, July 13, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxy...

GlobeNewsWire - 6 months ago

DUBLIN, Ireland, July 01, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium ox...

GlobeNewsWire - 7 months ago

DUBLIN, Ireland, June 08, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxy...

Zacks Investment Research - 7 months ago

Avadel (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

The Motley Fool - 7 months ago

One is a blue chip, the other a small-cap, but both are innovators with significant growth opportunities.

Other stocks mentioned: REGN
Seeking Alpha - 8 months ago

Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Avadel's (AVDL) first quarter 2020 earnings and revenues surpass expectations.

GlobeNewsWire - 8 months ago

DUBLIN, Ireland, April 28, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium o...

Zacks Investment Research - 8 months ago

On Avadel's (AVDL) Q1 earnings call, investor focus will be on the company's lead candidate, FT218, currently being evaluated to treat excessive daytime sleepiness and cataplexy in narcolepsy ...

GlobeNewsWire - 8 months ago

DUBLIN, Ireland, April 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium o...

The Motley Fool - 8 months ago

Investors are excited about positive late-stage results for its narcolepsy drug.

Benzinga - 8 months ago

In the current session, Avadel Pharmaceuticals Inc. (NASDAQ: AVDL) is trading at $12.95, after a 31.74% increase.

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Avadel Pharmaceuticals.

Zacks Investment Research - 9 months ago

Avadel Pharmaceuticals (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 9 months ago

Investors need to pay close attention to Avadel Pharmaceuticals (AVDL) stock based on the movements in the options market lately.

GlobeNewsWire - 9 months ago

Topline data from the REST-ON study expected in Q2 2020 Topline data from the REST-ON study expected in Q2 2020

Seeking Alpha - 10 months ago

Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

A Seldom Discussed Detail Reignites The Avadel Bullish Case

The Motley Fool - 10 months ago

Can these high-flying biotech stocks keep up their sizzling momentum?

Other stocks mentioned: ABEO, RCUS
The Motley Fool - 10 months ago

An infusion of cash is just what the doctor ordered.

GlobeNewsWire - 10 months ago

DUBLIN, Ireland, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium ox...

Zacks Investment Research - 1 year ago

Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 1 year ago

Though international markets trailed the U.S. market in 2019, there are hidden gems that crushed the S&P 500 this year on stock-specific strength.

Other stocks mentioned: EDU, RCEL, SBGL, VIPS
Zacks Investment Research - 1 year ago

Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.

GlobeNewsWire - 1 year ago

- - - A total of 212 patients enrolled in the REST-ON study exceeds the trial’s enrollment target of 205 - - - Topline data from the REST-ON study expected in Q2 2020

The Motley Fool - 1 year ago

The biotech received an FDA approval, but the launch timing is uncertain.

GlobeNewsWire - 1 year ago

USPTO issues Orange Book-listed patent for Nouress USPTO issues Orange Book-listed patent for Nouress

GlobeNewsWire - 1 year ago

DUBLIN, Ireland, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium ox...

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for December 9th

Other stocks mentioned: AQST, GRBK, IDN
GlobeNewsWire - 1 year ago

- - - Thomas S. McHugh appointed as Chief Financial Officer - - - Dr. Jason Vaughn appointed Senior Vice President of Technical Operations

24/7 Wall Street - 1 year ago

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval.

Other stocks mentioned: ACAD, ALEC, AMRN, BHC, BIIB, EPZM, GTHX, MGNX, SYRS
Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Avadel Pharmaceuticals.

GlobeNewsWire - 1 year ago

205 patients enrolled; additional patients currently in screening will be allowed to enroll if eligible

Seeking Alpha - 1 year ago

Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

DUBLIN, Ireland, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcole...

About AVDL

Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicate... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jun 7, 1996
CEO
Gregory Divis
Employees
50
Stock Exchange
NASDAQ
Ticker Symbol
AVDL
Full Company Profile

Financial Performance

In 2019, AVDL's revenue was $59.22 million, a decrease of -42.66% compared to the previous year's $103.27 million. Losses were -$33.23 million, -65.14% less than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for AVDL stock is "Strong Buy." The 12-month stock price forecast is 17.88, which is an increase of 168.07% from the latest price.

Price Target
$17.88
(168.07% upside)
Analyst Consensus: Strong Buy